QUEBEC, April 4 /CNW Telbec/ - Victhom Human Bionics Inc., ("Victhom")
(TSX: VHB), announced today that Mr. Martin LeBlanc had joined its Board of
Directors on March 23rd, 2007. "Mr. LeBlanc will be bringing exceptional
expertise to Victhom, and his experience will be especially relevant and
useful for the future development of the Company" said Mr. Daniel Johnson,
Chairman of the Board.
Mr. LeBlanc is currently President of Caprion Proteomics. He was a
Co-founder of Caprion Pharmaceuticals and served as its Chief Operating
Officer from 2000 to 2007. Prior to that, he was successively a management
consultant with McKinsey & Company, VP of Sales & Marketing at Advanced
Bioconcept Ltd. and its General Manager after its acquisition by NEN Life
Sciences (now Perkin-Elmer). He is also Co-chair of Montreal In-Vivo, and a
member of the Board of Directors of the Atlantic Cancer Research Institute.
Mr. LeBlanc holds a B.Sc.Soc. from the University of Moncton (N.-B.) and an
M.A. from Oxford University where he was a Rhodes Scholar.
Mr. André Monette has decided not to seek re-election for the position of
Director at the next annual meeting, and he has chosen to leave the Board of
Directors on April 2, 2007.
Victhom researches, develops and delivers bionic devices that treat a
variety of physiological dysfunctions. Victhom has two business units:
BioTronix and NeuroBionix.
Victhom manages a portfolio of 37 granted and 82 pending patents filed in
various countries and 13 registered trademarks worldwide. Victhom has
established an ongoing process to ensure the protection of its intellectual
property and to pursue filings for any discovery or improvements to its
For further information:
For further information: Mr. Daniel Johnson, Chairman of the Board,
(514) 397-4161, Fax: (514) 875-6246, email@example.com; Media Relations:
Frédéric Tremblay, HKDP Communications and Public Affairs, (514) 395-0375,
ext. 234, firstname.lastname@example.org; Source: Victhom Human Bionics Inc.,